Key Summary Points {#d30e345}
==================

***Why carry out this study?***Diabetic foot ulcer (DFU) is a costly complication of diabetes, with the extent of costs related to the frequency and duration of hospitalizations, amputations, ambulatory follow-up, transportation costs and disruptions to daily working activities.Telemedicine has been extensively studied for the management of diabetic subjects in general and has also proved to be effective in reducing and improving glycaemic balance in diabetic patients; however, very few telemedicine studies on the management of DFU have been conducted to date.The main objective of this study is to assess whether telemedicine can significantly reduce the number of days of hospitalization associated with foot ulcers in diabetic subjects.***What was learned from the study?***The design of the telepied study is described; recruitment for the study ended in May 2019 with a total of 180 patients.

Context {#Sec1}
=======

Diabetic foot ulcer (DFU) is a major public health issue worldwide in patients with diabetes \[[@CR1]\]. It is associated with poorer survival and functional outcomes and a high recurrence rate \[[@CR2]\]. DFU is one of the leading causes of lower limb amputation \[[@CR3]\], with some 50% of non-traumatic amputations being performed in diabetic patients \[[@CR4], [@CR5]\]. It is also characterized by slow and difficult healing and associated with a high risk of amputation and infectious complications \[[@CR6]\], as evidenced by such patients having a mortality rate at 5 years equivalent to that of colon cancer patients \[[@CR7]\]. DFU is a complication associated with high treatment costs \[[@CR8]\], with the extent of costs related to the frequency and duration of hospitalizations, need for amputation, ambulatory follow-up, transportation costs and disruption to daily working activities (with the latter costs also corresponding to one of the indirect costs of DFU management). A survey conducted by the Institute for Health Watch reported that, in France, the number of hospitalizations associated with DFU increased by fivefold in the 10 years between 1997 and 2007.

The use of telemedicine in general for the management of diabetic subjects has been extensively studied \[[@CR9]\]. More specifically, telemedicine has been proven to be effective in reducing and improving glycaemic balance in diabetic patients \[[@CR10]\]. However, very few telemedicine studies have been conducted to date on the management of DFU \[[@CR11]\]. A systematic review shows that the application of telehealth and telemedicine approaches for the management of DFU is still in its infancy \[[@CR12]\], but this method seems to be more appreciated by and more satisfying to patients \[[@CR13]\].

The main objective of the study described here is to assess whether telemedicine and management by a referral nurse can significantly reduce the number of days of hospitalization associated with foot ulcers in diabetic subjects. We believe an assessment of the combination of these two treatment strategies for patients with DFU is more appropriate than an assessment of the impact of telemedicine alone versus standard care.

Description and Rationale of the Study Method {#Sec2}
=============================================

This is a controlled single-centre study in open, parallel groups of diabetic patients with de novo foot ulcer or recurrence of a previously healed ulcer.

The study protocol was approved by the French National Agency for Medicines and Health Products Safety (ANSM) and by the ethics committee of Pitie Salpetrière University Hospital (Institutional Review Board; Agreement of US Department of Health and Human Services No. RCB:2016-A01136-45). Comprehensive information on the study was provided to each patient on a form printed specifically for this purpose, who must then provide written informed consent before enrolment.

Study Objectives {#Sec3}
================

Main and secondary objectives {#Sec4}
-----------------------------

The main study objective is to show that the total number of days of hospitalization to healing of a de novo foot ulcer in a diabetic patient is lower in the experimental Télépied Follow-Up group (Télépied group) than in the Standard Follow-up control group.

The secondary objectives are: (1) to show that the healing time for DFU is not higher in the Télépied group than in the Standard Follow-Up group and (2) to compare the total cost of direct care for the Télépied group versus the Standard Follow-up control group.

Primary Evaluation Criterion {#Sec5}
----------------------------

The primary evaluation criterion was comparison of the total number of days of hospitalization over 1 year or until complete healing of the DFU in the Télépied group versus the Standard Follow-Up group. Patients are hospitalized if they present aggravated ulcers requiring hospitalization and characterized by one or more of the following factors: (1) increased lesion area or depth; (2) appearance of signs of local infection; (3) signs of generalized infection.

Participants {#Sec7}
------------

### Inclusion Criteria {#Sec8}

The inclusion criteria are: (1) patients with type 1 or type 2 diabetes aged \> 18 years who have been hospitalized or who have been seen by attending physicians in the diabetology ward for either a de novo foot ulcer or recurrence of a previously healed ulcer; (2) patients who have agreed to take part in the study and have provided signed informed consent; (3) patients whose healthcare is covered by social security.

### Non-inclusion Criteria {#Sec9}

Pregnant women, patients deprived of liberty by judicial or administrative decision, persons subject to legal protection measures or patients taking part in another clinical trial were excluded from participating in the study.

Description of the Study Tools {#Sec10}
------------------------------

### Photography {#Sec11}

In both groups, the referral hospital nurse takes a picture of the ulcer at each hospital visit after cleansing the ulcer and providing local care. In the Télépied study group, the independent nurse also takes a photograph of the foot ulcer being investigated in the study during home visits conducted every 1 or 2 weeks. All photographs of ulcers will contain a ruled edge subdivided into millimetres that enables calibration of the photograph using the measuring software.

### Measurement of Ulcer Area {#Sec12}

The area of each plantar ulcer will be measured and calculated using Tracer*.exe* software developed by the University of Glamorgan (Pontypridd, Wales, UK) \[[@CR14]\].

### Adjudication Committee {#Sec13}

The adjudication committee will have two main tasks: (1) to assess the course of ulcer healing and (2) to evaluate the therapeutic decisions made by the investigating doctor in order to eliminate any bias that the investigator might introduce with regard to the primary evaluation criterion.

Each ulcer photograph for a given patient will be analysed independently by the members of the adjudication committee. A consensus decision will then be made between the three members of the adjudication committee. Each therapeutic decision will be independently evaluated by the adjudication committee members who will determine whether or not the decision is warranted in the light of progress in treatment of the ulcer or in the patient\'s state of health.

Complete healing of the DFU investigated in the study is defined as complete epithelialization of the ulcer once the possibility of hyperkeratosis has been ruled out.

Study Conduct {#Sec14}
-------------

### Selection Visit {#Sec15}

During their visits with the investigator at regular consultations or during hospitalization in the diabetes department, patients meeting the inclusion criteria are invited to take part in the study. If necessary, a cooling-off period may be considered, and patients may return to the centre later for the inclusion visit. For patients agreeing to participate in the selection visit, inclusion can be completed on the same day.

### Inclusion Visit (V0) {#Sec16}

Patients receive information from the investigating doctor on the study aims and conduct. They are provided with the patient information sheet and the informed consent form. They are asked to read the information sheet and then to date and sign the consent form prior to participating in any study-related procedures.

Patients included are assigned to a follow-up group based on the following defined schedule: patients presenting for their first visit during an odd week will be assigned to the Standard Follow-Up control group (Group 1); patients presenting for their first visit during an even week will be assigned to the Télépied Follow-Up study group (Group 2). Allocation to groups is to occur in an alternating fashion throughout the study inclusion period, i.e. a period of 6 months.

Key Data Collected {#Sec17}
------------------

The key data collected are the inclusion criteria, non-inclusion criteria, demographic data, clinical data (glycated haemoglobin, current treatment, systolic/diastolic blood pressure, disease history, diabetes complications, description of the ulcer being followed up in the study, photograph of the ulcer with planimetric measurement of its area and estimated depth and presence of infection or ischaemia.

Standard Follow-Up Control (Group 1) {#Sec18}
------------------------------------

At the end of their V0 inclusion visit, during hospitalization or during a consultation visit, patients will receive follow-up visits to monitor their ulcers at a rate determined by the investigating doctor. At each visit, the investigating doctor performs a standard follow-up procedure.

Between hospital visits, patients may be assigned to one of the three subgroups defined by type of care:Subgroup 1: Patients return home. Daily local ulcer care is given by an independent nurse.Subgroup 2: Patients are followed up during hospitalization.Subgroup 3: Patients are followed up at a follow-up and rehabilitation unit.

The follow-up period will be 12 months even if the ulcer is healed before this period

Télépied Follow-Up Study (Group 2) {#Sec19}
----------------------------------

Starting from their inclusion in the study, patients in the Télépied group are cared for by a referral nurse specially trained in diabetic foot ulcers.

At the end of their V0 inclusion visit, during hospitalization or during a consultation visit, patients will be assigned to one of the following three subgroups:Subgroup 1: Patients return home. Daily local foot ulcer care is given by an independent nurse.Subgroup 2: Patients are followed up during hospitalization.Subgroup 3: Patients are followed up at a follow-up and rehabilitation unit.

After their inclusion visit, patients hospitalized in the diabetes ward are followed by the referral nurse to arrange their discharge. Patients included during a consultation return home after the inclusion visit. A "planning" visit is scheduled by the referral nurse on discharge day + 1. This visit allows a personalized care plan to be put in place as well as consultation on methods for the transmission of information between the independent nurse responsible for local ulcer care at the patient\'s home and the referral nurse performing a follow-up visit every 7 or 15 days at the patient\'s home.

At each of these visits, the independent nurse provides local care for the patient\'s foot ulcer.

Once a week at the time of local care and dressing changes the independent nurse and/or patient must provide the referral nurse with a photograph of the foot ulcer being studied.

### Role of the Referral Nurse {#Sec20}

participating in informing/training patients on the management of their ulcer (discharge, daily care, etc.),monitoring patients for the duration of their hospitalization and organizing any necessary examinations as well as patient discharge from the hospital,arranging patients' discharge from hospital (whether returning home or other accomodation),assisting patients on their return home by making the arrangements for follow-up with an independent nurse,acting remotely as a reference for independent nurses who require advice or guidance in making care decisions,providing support to expert doctors at the hospital,organizing appointments and planning patient follow-up (additional examinations, re-hospitalization, consultations, etc.) together with the administrative staff in charge of coordinating consultations at the hospital,centralizing reporting by the various independent nurses and managing the transmission of information to medical experts,completing case report forms for the study.

### Role of the Investigating Doctor {#Sec21}

carrying out patient recruitment and supporting the referral nurse regarding medical follow-up,providing support for the referral nurse,validating the reports prepared by the reference nurse.

Data Analysis {#Sec22}
=============

Randomization: Assignment to a Follow-Up Group {#Sec23}
----------------------------------------------

Patients are not to be randomly assigned to one of the two groups but rather to be allocated according to a pre-decided schedule. Patients are automatically assigned to one or other of the groups studied according to the week of their first visit, with patients attending their first visit during an odd week assigned to the Standard Follow-up control group (Group 1), and those attending their first visit during an even week assigned to the Télépied Follow-up study group (Group 2). This methodology allows the referral nurse responsible for monitoring patients in the Télépied group to be present only when Group 2 patients are included, thereby avoiding potential bias or influence with regard to Group 1 patients, who are to be included in the study without the presence of the referral nurse. The allocation will also be made by block of predefined size. Randomization will be stratified according to the ankle-brachial index (ABI**)** measured during the inclusion visit, into three groups defined according to ABI \> 0.9, 0.7 \< ABI \< 0.9 and ABI \< 0.7. This stratification will make it possible to evenly distribute the patients suffering from severe arterial disease into the two treatment groups.

There are to be 180 evaluable patients.

The primary endpoint of the study as defined in the preceding text is the length of hospitalization during the post-hospital year for diabetic patients with DFU. Post-hospital follow-up of 185 patients with DFU resulted in a mean ± standard deviation of 27.25 ± 28.77 days of hospitalization per patient during the first year of follow-up. This mean and its standard deviation were taken as a reference for the control group in determining statistical power.

With the number of patients included in the analysis set at *N* = 90 per group and an alpha risk of 0.05 (two-sided), the following list shows the differences that can be detected between the two treatment groups with a statistical power of \> 80% and different observed standard deviation:a difference of 9 days for an overall standard deviation of 21,a difference of 10 days for an overall standard deviation of 23,a difference of 11 days for an overall standard deviation of 26,a difference of 12 days for an overall standard deviation of 28.

Data Analysis Strategy {#Sec24}
----------------------

A detailed analytical plan will be prepared before the database is frozen and validated by the study sponsor and the principal investigator.

### Evaluable Populations {#Sec25}

Evaluable population: all randomized patients with at least one item of follow-up data.Population evaluable for efficacy criteria (per-protocol population): all randomized patients presenting no major deviations.

Protocol deviations will be assessed during a blind review in order to define their severity and, based on their severity, a decision will be made on whether or not a given observation should be retained in the data analysis set.

### General Remarks on Descriptive Analyses {#Sec26}

All evaluation criteria will undergo a group-by-group analysis in terms of the following statistics:For quantitative variables: number of missing values, number of non-missing values, mean, standard deviation, median, first quartile, third quartile, minimum and maximum.For qualitative variables: number of missing values, number of non-missing values, frequencies, percentages for each modality of the variable (excluding missing data for the denominator).

### Analysis of the Main Objective {#Sec27}

The main objective of the study is to assess the superiority of the management of DFU via telemedicine versus standard follow-up.

Comparison of the mean number of days of hospitalization (associated with DFU) in each treatment group is to be tested using a variance analysis model that includes the stratification parameter. The null hypothesis tested will be equal distribution between the two groups of the number of days of hospitalization (associated with DFU) during the year following hospitalization.

The number of days are to be assessed for each group with a two-sided 95% confidence interval.

### Analysis of Secondary Criteria {#Sec28}

The means of the secondary quantitative criteria are to be compared using an analysis of variance model (including the stratification parameter) between the Télépied group and the Standard Follow-Up Control group. Secondary qualitative criteria will be compared using a logistic regression model (including the stratification parameter) between the Télépied group and the Standard Follow-Up Control group.

The two-sided 95% confidence interval will also be determined for each of the following secondary criteria: mean duration of hospitalization (for one DFU) for each patient,frequency of ulcerations for each patient,average duration of progression of ulceration for each patient,rate of healing for the foot ulcer analysed in the study,number of patients undergoing amputation during the 1-year follow-up period,change in patient satisfaction score (Diabetes Treatment Satisfaction Questionnaire \[DTSQ\]).

The total real per-patient cost of direct care associated with the presence of a DFU is the sum of the following costs (hospitalization costs + transportation costs + nursing costs + independent nursing costs + cost of materials + costs of consultations with doctors in private practice).

Type-1 Alpha Risk {#Sec29}
-----------------

The risk level for type-1 error in the analysis is set at 0.05 for a two-sided situation.

Study Organization and Progress {#Sec30}
-------------------------------

A total of 180 patients were included in the study, with the first inclusion taking place on 25 March 2017 and the last on 06 May 2019. At the time of submission of this article, 120 patients have completed the study. The final visit is scheduled for 07 May 2020. The main results will be published in 2020. Monitoring is to be carried out by the Centre for Studies and Research for Intensification of Diabetes Treatment (Evry, France).

Discussion {#Sec31}
==========

In this report we describe the rationale and design of the Télépied single-centre trial in diabetic subjects. The aim of this study is to compare the total duration of hospitalization over a 1-year follow-up required to achieve complete healing of a DFU using telemedicine management and a referral nurse versus the standard care pathway.

DFU continues to be inadequately studied and poorly funded, despite its prevalence and severity and the high social and economic burdens associated to it \[[@CR15]\]. The healthcare costs for patients with DFU are enormous and account for 25--30% of the total costs associated with all care provided to diabetic patients \[[@CR16], [@CR17]\]. In France, the hospitalization rate for diabetic foot continues to rise \[[@CR18]\], despite the presence of centres throughout the country specializing in its management. In real life, patients with DFU have little personalized follow-up, either at the referral centre or at their home.

Conclusions {#Sec32}
===========

The aim of the Télépied study is to demonstrate that personalized follow-up and telemedicine can reduce the need for hospitalization of a diabetic patient with DFU and, if required, shorten the duration of hospitalization by providing personalized advice targeted towards patients' individual profiles and the precise characteristics of their lesions.

Clinical Trials.gov identifier: NCT02986256.
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